Get started
Work

P86.08 Phase 2 Study of Zenocutuzumab (MCLA-128), a Bispecific HER2/HER3 Antibody in NRG1 Fusion-Positive Advanced Solid Tumors

Year: 2021
Type: conference-abstract
DOI: 10.1016/j.jtho.2021.01.1237
Authors: A. Schram, T. Macarulla, E. O’Reilly, J. Rodon, B. Wolpin, S. Ou, D. Kim, J.C. Yang, J. Lam, A. De Langen, V. Boni, G. Cerea, M. Duruisseaux, E. Felip, S. Liu, G. O'Kane, F. Senecal, M. Nagasaka, J. Starr, E. Wasserman, A. Drilon
Institutions: Memorial Sloan Kettering Cancer Center, Vall d'Hebron Hospital Universitari, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, University of California, Irvine, Seoul National University Hospital, National Taiwan University Hospital, National Cancer Centre Singapore, The Netherlands Cancer Institute, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Hospices Civils de Lyon, Hôpital Louis Pradel, Vall d'Hebron Institute of Oncology, Georgetown University, Princess Margaret Cancer Centre, Northwest Medical Specialties, The Barbara Ann Karmanos Cancer Institute, Mayo Clinic, Mayo Clinic in Florida, Merus (Netherlands)
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W3137863134
Cites:
Cited by: 2
Related to: 10